AI Terminal
Karolinska Development
Interim / Quarterly Report • Aug 29, 2025
3168_ir_2025-08-29_496457f9-a83e-4c1e-8f31-830e249c84be.pdf
Interim / Quarterly Report
Open in ViewerOpens in native device viewer
Karolinska Development
Karolinska Development (Nasdaq Stockholm: KDEV) is an investment company which offers a unique opportunity to participate in the growth in value of a number of Nordic life science companies with substantial commercial opportunities. All of the portfolio companies are developing potentially ground-breaking treatments for medical conditions with a substantial need for improved therapies, including priming of labor, brittle bone disease, liver diseases, Parkinson's disease, heart failure, sepsis, anemia in chronic kidney disease, nerve pain, serious viral infections, systemic fungal infections and low back pain. To date, two of the companies have launched their first products, and several companies are in late clinical phase with potential business opportunities over the next two years.
For further information, see www.karolinskadevelopment.com
Financial Update
- The net profit/loss for the second quarter was SEK -73.3 million (SEK -16.0 million in the second quarter of 2024). Earnings per share totaled SEK -0.3 (SEK -0.06 in the second quarter of 2024). Net profit/loss for the period January – June 2025 amounted to SEK -87.5 (-15.8) million.
- The result of the Change in fair value of shares in portfolio companies for the second quarter amounted to SEK -11.5 million (SEK -11.1 million in the second quarter of 2024). The result is mainly the effect of the downturn in share price in the listed holdings Modus Therapeutics and Promimic. Change in fair value of shares in portfolio companies for the period January – June 2025 amounted to SEK -15.0 (-9.2) million
- The total fair value of the portfolio was SEK 1,384.9 million at the end of June 2025, corresponding to a decrease of SEK 49.3 million from SEK 1,434.2 million at the end of the previous quarter. The net portfolio fair value at the end of June 2025 was SEK 1,058.9 million, corresponding to a decrease of SEK 44.2 million from SEK 1,103.1 million at the end of the previous quarter. The main reason for the net decrease in fair value was the divestment of Karolinska Development's shares in OssDsign and also the downturn in the share price of the listed holdings Modus Therapeutics and Promimic.
- The result of Change in fair value of other financial assets and liabilities (earn-out agreements) for the second quarter amounted to SEK -57.6 million (SEK 2.0 million in the second quarter of 2024). The result is mainly due to the valuation of the earn-out agreement with Organon (regarding the sale of Forendo) after Organon announced that they plan to discontinue the OG-6219 clinical development program. Change in fair value of other financial assets and liabilities for the period January – June 2025 amounted to SEK -63.7 (6.9) million.
Other financial assets, current and non-current, (earn-out agreements) amounted to SEK 18.6 million at the end of June 2025, a decrease of SEK 57.6 million from SEK 76.2 million at the end of the previous quarter.
Net asset value amounted to SEK 1,148.6 million, per share SEK 4.3, at the end of June 2025 (SEK 1,238.2 million, per share SEK 4.6 at the end of June 2024).
- Net sales totaled SEK 0.4 million during the second quarter of 2025 (SEK 0.5 million during the second quarter of 2024). Net sales for the period January – June 2025 totaled SEK 0.9 (1.0) million.
- Karolinska Development invested a total of SEK 1.8 million in portfolio companies during the second quarter of 2025 (SEK 10.7 million in the second quarter of 2024). Second quarter 2025 investments in portfolio companies by Karolinska Development and other specialized life sciences investors totaled SEK 159.9 million (SEK 38.7 million in the second quarter of 2024).
- Cash and cash equivalents increased by SEK 20.0 million, an effect of the divestment of Karolinska Development's holding in OssDsign, during the second quarter, totaling SEK 71.1 million on 30 June 2025 (SEK 49.7 million on 30 June 2024).
Significant events during the second quarter
- The portfolio company Umecrine Cognition presented recent preclinical data showing that golexanolone reverses dopamine loss and sustains improvements of Parkinsonian symptoms at the 19th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2025, in Vienna, Austria (April 2025).
- Karolinska Development announced that Viktor Drvota took over as CEO of the portfolio company Umecrine Cognition. Viktor Drvota remains the CEO of Karolinska Development (April 2025).
- The portfolio company OssDsign announced a change of CEO during the second half of 2025. The purpose is to support the establishment of leadership with an even stronger presence and focus on the US market (April 2025).
- The portfolio company Umecrine Cognition has been awarded a research grant by The Michael J. Fox Foundation (MJFF) amounting to USD 420,000. The grant will finance preclinical studies to evaluate the potential treatment effect of golexanolone in Parkinson's disease (April 2025).
- The portfolio company Umecrine Cognition attended the EASL Congress 2025 in Amsterdam, May 7–10, presenting validation and implementation data for its newly developed clinical scale for Primary Biliary Cholangitis, PBC (May 2025).
- The portfolio company OssDsign reached a new milestone with 10,000 patients treated with its innovative nanosynthetic bone graft OssDsign Catalyst on the US market (May 2025).
- At Karolinska Development's Annual General Meeting, it was decided, among other things, to adopt the profit and loss statement and the balance sheet as well as the consolidated profit and loss statement, the consolidated balance sheet, and to approve the allocation of the result, proposed by the Board of Directors and the CEO, to elect Anders Härfstrand to the Board of Directors and to re-elect Philip Duong, Anna Lefevre Skjöldebrand, Ben Toogood and Will Zeng to its Board of Directors, and to elect Ben Toogood Chairman of the Board (May 2025).
- The portfolio company Umecrine Cognition resumed the inclusion of patients to the clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. In March, Umecrine Cognition announced that the study had been halted due to technical issues in the production of capsules used in the study, which, however, had no impact on patient safety (May 2025).
- The portfolio company OssDsign has carried out a directed share issue through an accelerated bookbuilding procedure that brought the company approximately SEK 158 million. In connection
with the directed share issue, the company announced an updated strategy and revised its financial targets for the period 2025–2028 (June 2025).
- The portfolio company Modus Therapeutics carries out a fully secured rights issue of units of SEK 28.3 million. The proceeds from the rights issue are intended to finance the continued development of the drug candidate sevuparin in chronic kidney disease with anemia (June 2025).
- Karolinska Development divested its remaining shares in the portfolio company OssDsign and thereby strengthened the investment company's liquidity. The divestments provided Karolinska Development with a capital injection of approximately SEK 34.5 million (June 2025).
Significant post-period events
- Karolinska Development announced an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate (July 2025).
- The portfolio company Modus Therapeutics completed patient enrollment on schedule to the part 1 of its ongoing clinical phase 2a study with sevuparin, which is being evaluated as a treatment for patients with chronic kidney disease with anemia (July 2025).
- The portfolio company Umecrine Cognition raised SEK 24.6 million through a convertible loan to be used for the ongoing clinical Phase 1b/2a study of golexanolone in primary biliary cholangitis. The convertible loan with attached share options is directed to a consortium of existing long-term shareholders and investors in Umecrine Cognition, including Karolinska Development (July 2025).
- The portfolio company Modus Therapeutics raised SEK 28.3 million in a unit issue with a subscription rate of 189 percent. The proceeds from the rights issue are intended to finance the continued development of the drug candidate, sevuparin, for the treatment of chronic kidney disease (August 2025).
Viktor Drvota, CEO of Karolinska Development, comments:
"We have a clear strategy and a stable scientific foundation for all of the projects in our investment portfolio, and will navigate these choppy market waters by keeping our focus on patient benefit"
Contact information
For further information, please contact: Viktor Drvota, Chief Executive Officer +46 73 982 52 02 [email protected] Hans Christopher "HC" Toll, Chief Financial Officer +46 70 717 00 41 [email protected]
Chief Executive's Report
The second quarter of 2025 has been characterised by continued market turbulence, posing challenges both for the capital market as a whole and the pharmaceutical sector in particular. Tariffs and geopolitical anxieties are generating stresses in the financial markets and global economy, inhibiting risk appetite and willingness to invest alike. That having been said, we are seeing signs of light on the horizon, with important investments being made in innovative companies. The market may be anxious, but the need for medical breakthroughs remains. Our investment portfolio comprises promising medical innovations with the potential to revolutionise the treatment of a number of different medical conditions, and we will continue to focus our efforts on supporting the portfolio companies' development and commercialisation projects going forward.
Umecrine Cognition's clinical study resumes
Umecrine Cognition has resumed recruitment of patients to the company's primary biliary cholangitis (PBC) clinical study. The study, which is evaluating the golexanolone candidate drug, was paused in May due to technical problems in the production of the capsules used in the study. These problems had no impact on patient safety and by May, the problems had been rectified, and recruitment could resume.
In July, Umecrine Cognition raised SEK 24.6 million for the ongoing study through a convertible loan directed to a consortium of investors, including Karolinska Development. The study is scheduled for completion during the first half of 2026.
The EASL hepatology conference, held in May in Amsterdam, saw Umecrine Cognition present data validating the newly developed clinical scale for primary biliary cholangitis, which is now being used in the ongoing clinical study. The scale has been designed to enable the measurement of symptom severity in PBC patients that is not possible using conventional laboratory tests.
Umecrine Cognition has, furthermore, received a research grant totalling USD 420 thousand from The Michael J. Fox Foundation. The grant will be used to finance preclinical trials evaluating the potential treatment effect of golexanolone in Parkinson's disease. Golexanolone's effect on Parkinson's-related sleep disorders and cognitive impairments will be evaluated in several disease models, as will its effect on disease progression. The recognition that the grant represents is a significant acknowledgement of golexanolone's potential as a treatment option for Parkinson's disease and will enable the ongoing development of the candidate drug with a high medical need.
Modus carries out rights issue and achieves study milestone
Our portfolio company, Modus Therapeutics, which is developing the sevuparin drug candidate for the treatment of a number of inflammatory diseases, completed a rights issue of units in August, providing the company with SEK 28.3 million before issue costs. The issue was subscribed to 189 percent, an excellent outcome that also meant that no guarantee commitments were used. The proceeds will be used for the ongoing development of the candidate drug in chronic kidney disease with anaemia, and in particular, for the ongoing clinical phase 2 study. The company announced, after the period end, that it had completed patient enrolment on schedule. The conclusions of this first part of the study will determine the dose used in the next part of the phase 2 study, which aims to evaluate the therapeutic potential of repeated dosing – an important value-driving point in the development program.
Additional profits realised in OssDsign
In late June, we once again divested shares in our portfolio company, OssDsign (which is developing the next generation of orthobiologics) yielding a cash injection for Karolinska Development of SEK 34.5 million. Karolinska Development has been a long-term owner of OssDsign and was involved in the listing of the company on the NASDAQ Growth Market in 2019. OssDsign has demonstrated strong value growth recently, but we have now decided to prioritise other investments where we see value creation potential and a higher possible return on investment going forward. Karolinska Development has no direct ownership in OssDsign following the divestment, but does have an indirect holding via the KCIF Co-Investment Fund.
Update from Organon on endometriosis project
In early July, Organon issued an update on the development of the candidate drug, OG-6219, acquired through Organon's acquisition of Forendo Pharma in 2021. Organon is planned, based on the results of a clinical phase 2 study of endometriosis-related pain, to discontinue the OG-6219 clinical development program – a decision which will entail a depreciation for Karolinska Development due to the acquisition agreement's earn-out payments entitlement clause. The acquisition of Forendo included two candidate drug projects, of which OG-6219 was the most advanced drug development project.
Purposeful focus despite market turbulence
The market is unusually unpredictable at the moment, but we are continuing to work purposefully towards our internal goals while, at the same time, supporting our portfolio companies' efforts to achieve theirs. We have a clear strategy and a stable scientific foundation for all of the projects in our investment portfolio, and will navigate these choppy market waters by keeping our focus on patient benefit.
Solna, 29 Augusti 2025
Viktor Drvota Chief Executive Officer
Portfolio Companies
High potential for continued value inflection in portfolio
Karolinska Development's investments in therapeutic companies are conducted in syndicates with other professional life science investors, normally until proof-of-concept is demonstrated in phase 2 trials, at which point different exit options are evaluated. When engaging in MedTech companies, the business model is to finance the companies until they show a positive operating profit.
The portfolio, per June 30, 2025, consisted of eleven companies focused on developing innovative treatment methods for severe or life-threatening diseases where there is currently a great need and there is a lack of effective treatment alternatives. Nine of the portfolio companies have drug candidates in ongoing or planned clinical trials and two companies have MedTech products in commercial phases. During the period 2025–2026, one portfolio company is expected to report phase 1 results, and four portfolio companies are expected to present data from phase 2 studies. SVF Vaccines is preparing a Phase 1 program, and PharmNovo will soon start its Phase 2 study. Dilafor and BOOST Pharma are preparing to start phase 3 studies. These study results could significantly strengthen the potential for attractive divestments or licensing deals. In recent years, comparable drug candidates have been out-licensed or sold for individual deal values reaching several billion SEK.
In addition to the portfolio companies, Karolinska Development holds an earn-out agreement with Organon related to the acquisition of Forendo Pharma. The agreement includes potential milestone payments linked to both drug development and future commercialization. Following Organon's update regarding the development of the drug candidate OG-6219, which is based on results from a Phase 2 clinical study in endometriosis-related pain, Organon plans to discontinue the development program with OG-6219, resulting in an impairment loss for Karolinska Development since the acquisition agreement included the right to additional purchase prices. As part of the acquisition, two drug candidates were included, of which OG-6219 was the most advanced drug development project.
Project (First-in-class) Tafoxiparin
Primary indication Priming of Labor
Development phase Phase 2b complete Phase 3 ready
Holding in company* Karolinska Development 3% KDev Investments 29%
Other investors Opocrin The Foundation for Baltic and East European Studies Lee's Pharmaceutical Praktikerinvest Rosetta Capital
Origin Karolinska Institutet
More information dilafor.com
* Fully-diluted ownership based on current investment plans.
Deal values for similar projects
- USD 500 million ObsEva (licensor) & Organon (licensee) 2021
- USD 397 million Velo Bio (seller) & AMAG Pharmaceuticals (buyer) 2018
Priming of labor reduces maternal and neonatal complications
Dilafor (Solna, Sweden) is developing tafoxiparin, a heparin analogue, aimed at priming spontaneous onset of labor leading to a normal vaginal delivery and minimizing the risk for maternal and fetal complications associated with labor induction. Over 30 percent of all pregnant women undergo induction in labor, with induction methods such as prostaglandins and oxytocin, requiring fetal and maternal surveillance in hospital due to high risk of complications for both mother and fetus. Clinical guidance for labor induction have recently been revised to encourage delivery as early as gestational week 39 in the US and weeks 40–41 in Europe, to reduce the risk of complications such as stillbirth, neonatal complications and to improve operative deliveries leading to improved maternal and neonatal outcomes The new guidance will increase the number of deliveries requiring initiation of labor, and thus new, safer treatment options are essential in obstetric care. Tafoxiparin is a patented substance that supplements the remodeling process of the cervix and uterus required for a natural spontaneous onset of labor. Tafoxiparin is planned to be safely administered at home, freeing up hospital beds and resources that would otherwise be required for the induction process.
Tafoxiparin has been shown to be safe for both mother and child in a phase 2a clinical trial with 263 pregnant women. In a subsequent phase 2b trial with 170 first-time mothers undergoing priming of labor showed significant results in the highest dose group. In an extension of the phase 2b trial with 164 additional women, positive results were also shown in lower doses. Dilafor has completed successful meetings with the US FDA and the European Health Agencies and is now preparing the phase 3 of tafoxiparin.
The market
Dilafor AB
Over 30 percent of all pregnant women need labor induction. The current standard treatment includes administration of prostaglandins and oxytocin. Frequently the induction fails, leading to slow progress of labor, operative deliveries, or other maternal and fetal complications. Market analyses show that a drug with a good effect on initiation of labor has the potential to reach annual sales over USD 1 billion in the US market alone.
Recent progress
In January 2025, Dilafor announced successfully having completed regulatory meetings with the FDA, and European Health Agencies, regarding the continued development of tafoxiparin. The completed meetings marked the end of a comprehensive dialogue with regulatory authorities to reach an alignment on designing pivotal clinical phase 3 studies in Europe and the US.
Expected milestones
• Start of phase 3 study with tafoxiparin for priming of labor.
Project (First-in-class) BOOST Cells
Primary indication Osteogenesis Imperfecta
Development phase Phase 2 reported Preparing phase 3
Holding in company* Karolinska Development 14%
Other investors
Industrifonden Origin Karolinska Institutet
More information boostpharma.com
*Ownership based on current investment plans
Deal values for similar projects
USD 535 million IPSEN (licensee) & Blueprint medicines (licensor), 2019
USD 304 million Ultragenyx (licensee) & Mereo BioPharma (licensor), 2020
BOOST Pharma ApS
Cell therapy reducing fractures in rare bone disease
BOOST Pharma (Copenhagen, Denmark) is developing a first-in-class and potentially groundbreaking cellbased treatment of the rare bone disease Osteogenesis Imperfecta (OI), also known as brittle bone disease. OI is a congenital condition that is caused by gene mutations that code for bone formation and lead to fragile bones, constant fractures and bone deformity leading to much pain, stunted growth and limited mobility.
BOOST Pharma's novel cell therapy is based on mesenchymal stem cells (MSCs), which are stem cells with high bone-forming capabilities. In September 2024, BOOST Pharma presented positive top line results from BOOSTB4, which is a phase 1/2 clinical study. The results showed that the treatment was safe and well tolerated both when administered before and after birth. The results also showed that fracture rates were reduced by over 75 percent, up to twelve months after the last dose.
A previous study, a human proof-of-concept study with four children with moderate to severe types of OI, also showed great promise; A significant reduction of fractures was observed; the children followed their own growth curve, and grew in length faster, compared to other OI patients, and the cells showed great safety.
The cell therapy is uniquely positioned in that treatment can start directly at diagnosis, either at the prenatal stage, or after the child is born. By starting treatment early, the benefits for the patient increase in later years. The cell therapy targets the underlying cause of the disease, which is defective collagen production in the bones, while other treatments target symptom relief and management.
BOOST Pharma has received Rare Pediatric Disease designation in the U.S. and Orphan Drug Designation in both the US and EU.
The market
There are very few therapies available and those that exist, such as physiotherapy, surgery, and bisphosphates (BPs), are merely palliative and fail to reduce the frequency of fractures. Generally, OI sufferers have an almost normal life span with severe disabilities due to bone defects and hundreds of painful bone fractures, even during fetal life, causing irreversible damage. Approximately 4,000 children are born worldwide each year with severe OI.
Recent progress
- In September 2024, BOOST Pharma announced positive top line results from a phase 1/2 study with over 75 percent reduction in fracture rates in children with OI.
- In November 2024, BOOST Pharma announced the successful completion of a pre-IND meeting with the US FDA for its allogeneic cell therapy in Osteogenesis Imperfecta. The FDA fully accepted the proposed clinical development plan, enabling BOOST Pharma to begin preparations for a pivotal Phase 3 study in the US and Europe.
Expected milestones
A registration-enabling phase 3 study is expected to start early in 2026.
Project (First-in-class) Golexanolone (GR3027)
Primary indications Primary biliary cholangitis (PBC) Parkinson's disease
Development phase Phase 2
Holding in company* Karolinska Development 62%
Other investors Fort Knox Förvaring AB PartnerInvest
Origin Umeå University
More information umecrinecognition.com
* Fully-diluted ownership based on current investment plans.
Deal values for similar projects
- USD 794 million Intercept Pharmaceuticals (seller) & Alfasigma (buyer) 2023
- USD 601 million GENFIT (licensor) & IPSEN (licensee) 2021
Umecrine Cognition AB
Developing a new and safe approach to treat cognitive impairment
Umecrine Cognition (Solna, Sweden) is developing golexanolone (GR3207), a candidate drug in a new class of pharmaceuticals that affect the GABA system, the chief inhibitory neurotransmitter in the central nervous system. The GABA system is suspected of being overactivated in liver failure and in other severe inflammatory diseases such as Parkinson's disease, causing very serious clinical symptoms, including cognitive impairments and sleep disturbances. Golexanolone counters the increased activation of the GABA system and has been shown to restore different types of neurological impairments in experimental models.
Umecrine Cognition is developing golexanolone for two indications: Primary Biliary Cholangitis (PBC) and Parkinson's disease. The company has also conducted a phase 2a clinical study of golexanolone in patients with Hepatic encephalopathy (HE), which is a serious neuropsychiatric and neurocognitive condition that occurs in acute and chronic liver damage. The results showed that the drug candidate was well tolerated and exerts a significant effect on brain signaling, with a correlated positive effect on extreme daytime fatigue. Based on these study results, the company has established a plan for the further development of the drug candidate PBC, where extreme daytime fatigue is one of the disease's most debilitating symptoms that prevents patients from living a normal life. The company is currently conducting a phase 2 study in PBC. Golexanolone has also been tested in preclinical models of Parkinson's disease which showed positive effects on symptoms and neuroinflammation as well as sustained effects on dopamine signaling.
The market
PBC is a rare autoimmune liver disease that attacks the bile ducts and mainly affects women. Common symptoms include fatigue, cognitive impairment, itching and, in more advanced cases, jaundice. The global market for the treatment of PBC was estimated at USD 584 million in 2021 and is expected to reach USD 3 billion by 2027.
Parkinson's disease is a neurodegenerative disorder that causes severe cognitive impairment and impairs motor functions. Approximately 10 million people worldwide suffer from the disease. Current medications mainly target motor functions and there is a lack of treatments for cognitive impairment. The global market for this type of treatment was valued at USD 3.4 billion in 2019 and is expected to grow by more than 6 percent per year until 2029.
Recent progress
- In May 2025 Umecrine Cognition received a research grant from The Michael J. Fox Foundation to support preclinical evaluation of golexanolone in Parkinson's disease.
- In the same month, Umecrine Cognition presented validation data for the new CGI-S-PBC™ clinical scale at the EASL Congress 2025.
- Also in May 2025, patient inclusion resumed in the ongoing Phase 1b/2a study of golexanolone in PBC, after resolving temporary manufacturing issues.
- In July 2025, Umecrine Cognition raised SEK 24.6 million through a convertible loan to fund the ongoing Phase 1b/2a study of golexanolone in PBC.
Expected milestones
Topline data from the phase 2 study of golexanolone in patients with PBC are expected in early 2026.
Project (First-in-class) Sevuparin
Primary indication Anemia chronic inflammation/ kidney disease Sepsis/Septic shock Severe malaria
Development phase Phase 2
Holding in company* Karolinska Development 66% KDev Investments 8%
Other investors Hans Wigzell Anders Bladh John Öhd
Origin Karolinska Institutet Uppsala University
More information modustx.com
*Fully-diluted ownership based on current investment plans
Modus Therapeutics AB
Develops sevuparin for life threatening diseases
Modus Therapeutics AB (Stockholm, Sweden) is developing the drug candidate sevuparin for the treatment of both acute and chronic severe conditions. The company's clinical project portfolio includes anemia associated with chronic inflammation and kidney disease, sepsis/septic shock, and severe malaria.
At the end of 2024, Modus Therapeutics initiated a phase 2 clinical study to evaluate sevuparin as a treatment for chronic kidney disease with anemia. The study consists of two parts: the first assesses safety and determines dosage for sevuparin through single-dose administration to patients with varying degrees of renal impairment, as well as a small reference group of healthy volunteers. The second part will focus on the effects of repeated doses and clinical outcomes, including hemoglobin levels, kidney function, hepcidin levels, and other biomarkers in patients with advanced chronic kidney disease and anemia. Research has shown that elevated hepcidin levels contribute to disrupted iron availability in chronic kidney disease and other chronic inflammatory conditions, worsening anemia associated with these diseases.
Sepsis/septic shock is a life-threatening medical condition for which there are currently no effective medical therapies. Patients with sepsis are at risk of developing multiple organ failure, and in severe cases, death. Data from preclinical animal models and human cell studies have shown that sevuparin may protect blood vessels and counteract plasma leakage during systemic inflammation.
In severe malaria, sevuparin is being developed as an adjunct therapy, administered before standard antimalarial treatment takes effect. Sevuparin is currently being evaluated in a clinical study conducted in collaboration with Imperial College London at trial sites in Kenya and Zambia.
The market
An estimated 10 percent of the world's population is believed to have grade 3-5 chronic kidney disease. Among these patients around 25 percent are expected to develop anemia, corresponding to approximately 4-5 million individuals in the United States alone. Limited response to current standard treatments often makes it difficult to maintain effective long-term management of the disease. Septic shock is a leading cause of death in intensive care units, with mortality rates often exceeding 30 percent. No specific drug treatment is currently available, making it one of the most costly conditions to manage in hospital care. In 2019, sepsis-related healthcare costs in the United States were estimated at USD 23 billion.
Recent progress
- In May 2025, Modus Therapeutics presented new preclinical data on sevuparin in chronic kidney disease at the BioIron Congress and in June at the EHA Congress.
- In July 2025, the company announced that patient recruitment for Part 1 of the Phase IIa study in chronic kidney disease with anemia had been completed according to plan.
- In August 2025, the company announced it was on track to initiate Part 2 of the Phase IIa study of sevuparin in chronic kidney disease with anemia.
- In August 2025, the company announced the outcome of the fully guaranteed rights issue announced in June. The issue was oversubscribed to 189% and provided the company with approximately SEK 28.3 million.
Expected milestones
The second part of the phase 2 clinical study with sevuparin in chronic kidney disease with anemia is expected to be initiated at the end of 2025.
Project (First-in-class) AC01
Primary indication Heart failure
Development phase Phase 2
Holding in company* Karolinska Development 10%
Other investors
Flerie Invest LLD Nybohov Invest Industrifonden 3B Health Ventures Novo Holdings Pureos Bioventures Sound Bioventures
Origin Karolinska Institutet Karolinska University Hospital
More information anacardio.com
Deal values for similar projects
- USD 1.1 billion Cardior Pharmaceuticals (seller) & Novo Nordisk (buyer) 2024
- USD ~1.8 billion CinCor Pharma (seller) & AstraZeneca (buyer) 2023
New treatment concept that enhances the heart's pumping ability in conjunction with heart failure
AnaCardio (Stockholm, Sweden) is developing a new treatment that enhances the heart's pumping ability in conjunction with heart failure. Heart failure occurs when the heart's ability to pump sufficient blood to meet the body's needs has deteriorated. The underlying condition often involves a weakening of the heart's musculature, resulting in an inability to pump the blood out of the heart's chambers. The condition arises as a sequela of high blood pressure or vasoconstriction. The chronic phase is characterized by diffuse symptoms, such as tiredness or breathlessness, which leads to the illness often being diagnosed at a late stage. Acute heart failure results in an individual's health status becoming critical, necessitating hospitalization. A major issue with existing pharmaceuticals is that they are not designed for long-term treatment.
AnaCardio is developing AC01, a small molecule that mimics the mechanism of action of the peptide hormone ghrelin. Treatment with ghrelin has been shown in previous studies to have a positive effect on the heart's pumping ability and can lead to a significant increase in the volume of blood pumped out of the heart. The drug candidate is being developed to restore the heart's normal muscular function and blood circulation with a new and safer technique. The Company's goal is to develop an oral drug that, in contrast to existing treatments, can affect the underlying cause of the disease. The drug candidate is based on research by Professor Lars Lund at Karolinska Institutet.
The market
AnaCardio AB
It is estimated that more than six million individuals in the US and nearly 100 million globally suffer from heart failure. The risk of developing a cardiovascular disease increases with age, and 10-20 percent of the elderly population is now estimated to suffer from chronic heart failure, which is now the most common reason for hospitalization amongst the elderly. Heart failure not only causes considerable individual suffering, but it also has significant economic consequences for society in the form of both direct costs from in-patient care and indirect costs such as productivity losses. The increased medical need is reflected in the sales value of heart failure treatments, which is expected to increase from USD 6.8 billion in 2021 to USD 18.7 billion by 2028 in the world's seven largest pharmaceutical markets.
Recent progress
- In January 2025, the company announced that it had secured SEK 205 million in new financing in a round led by Novo Holdings, Pureos Bioventures and Sound Bioventures.
- In February 2025, the company announced that the first patient in the second part of the phase 1b/2a clinical trial GOAL-HF1 had been dosed.
- In March 2025, the company announced that it had been granted an EU patent for the drug candidate AC01 as an inotropic treatment. The patent is jointly owned by AnaCardio and Helsinn Healthcare SA and provides exclusivity in all major European markets until 2042.
- In July 2025, AnaCardio received positive scientific advice from both the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF.
Expected milestones
Phase 2a expansion of the ongoing phase 1b/2a study, has a planned readout by the end of the year.
Project (First-in-class) PN6047
Primary indication Allodynia/ Hyperalgesia
Development phase Phase 1 complete Phase 2 ready
Holding in company* Karolinska Development 20%
Origin Start-up
More information pharmnovo.com
*Fully-diluted ownership based on current investment plans
Deal values for similar projects
- USD 630 million Eli Lily (licensee) & Confo Therapeutics (licensor) 2023
- USD 940 million ACADIA Pharmaceuticals (acquirer) & CerSci Therapeutics (acquired) 2020
PharmNovo AB
New potential treatment for difficult-to-treat nerve pain
PharmNovo (Lund, Sweden) is developing innovative drugs for the treatment of nerve pain (neuropathic pain), that is difficult to treat and often develops into a chronic condition. Nerve pain is one of the most prevalent types of chronic pain and affects up to 10 percent of the population. Common underlying causes include nerve damage from type 2 diabetes, shingles, trauma (including surgery), cancer, and cancer treatments. PharmNovo's lead candidate, PN6047, focuses on allodynia and hyperalgesia, two common forms of nerve pain, affecting 15-20 percent of neuropathic pain patients. Allodynia is pain due to a stimulus that does not usually provoke pain, while hyperalgesia is an increased pain from a stimulus that usually provokes pain. Current treatment options are deemed ineffective and are also associated with significant side-effects; particularly cardiovascular risks, and, with gabapentinoids or conventional opioids, a higher risk of suicide and drug abuse potential.
PharmNovo's novel drug candidate PN6047 targets a different receptor than conventional opiate drugs do; the delta opioid receptor, and thereby decreases the chronical pain without the side-effects associated with the currently marketed opioids (constipation, physical dependence and, potentially, fatal respiratory depression). PN6047 has completed a clinical phase 1 study showing that PN6047 is safe and well-tolerated at doses predicted to have clinically relevant effects. The drug candidate does not induce drug abuse behavior in nonclinical test models and indicates the capacity to reduce conventional opioid withdrawal symptoms, according to results from a collaboration with researchers at the University of Washington and the University of Michigan, with financial support from the US National Institute of Drug Abuse (NIDA). PharmNovo is now preparing a phase 2 clinical study which is expected to start in 2026.
The market
The need for improved treatments for nerve pain is enormous. Around 10 percent of the world's population currently suffers from conditions characterized by this form of pain, leading to a severely reduced quality of life for the individual and substantial costs for society – estimated at nearly EUR 440 billion annually in Europe alone. The estimated global market value for nerve pain drugs is nearly USD 6 billion per year and the market for allodynia alone is around USD 1.25 billion per year and is expected to continue to grow, driven by an aging population and increased cancer survival.
Recent progress
- In March 2025, the company announced that it had received positive feedback regarding the company's drug candidate, PN6047, in connection with a pre-IND meeting with the US Food and Drug Administration (FDA). Based on the feedback, PharmNovo plans to apply for an IND with the FDA before the end of 2025.
- In July 2025, PharmNovo announced that it had submitted a clinical trial application (CTA) in Spain for a Phase IIa proof-of-concept study of PN6047 in patients with neuropathic pain.
Expected milestones
The phase 2 study with PN6047 is expected to start in Q1 2026.
Project (First-in-class) SVF-001 SVF-002
Primary indication Hepatitis B and D SARS-CoV-2 and other coronaviruses
Development phase Phase 1
Holding in company* Karolinska Development 33%
Origin Karolinska Institutet
More information svfvaccines.se
*Fully-diluted ownership based on current investment plans
Deal values for similar projects
- USD ~1 billion Janssen Pharmaceuticals (licensor) & GSK (licensee) 2023
- EUR 1.45 billion MYR GmbH (acquired) & Gilead Sciences Inc (buyer) 2020
SVF Vaccines AB
New technology for the treatment of viral diseases
SVF Vaccines (Solna, Sweden) develops therapeutic proteins and DNA vaccines against, among other things, hepatitis D and B, as well as vaccines to prevent infections by covid-19 and potential future coronaviruses. Therapeutic vaccines, unlike preventative vaccines, have the potential to cure already infected patients.
Despite the availability of preventative vaccines and antiviral treatments, over 250 million people live with a chronic hepatitis B infection. One million chronic carriers die each year due to complications caused by the virus, such as liver cirrhosis and liver cancer. Today, 15-25 million people worldwide live with an infection of the closely related hepatitis D virus, that only infects hepatitis B-carriers and exacerbates the progression of the disease.
SVF Vaccines uses a proprietary immunotherapy to produce a specific form of antibodies that blocks the ability of the hepatitis virus to invade human cells while also neutralizing the virus, with the vaccine candidate SVF-001. The company has generated promising efficacy data in preclinical animal models and is now preparing a phase 1 study in hepatitis D, that is expected to be initiated in 2026.
In October 2024, the company presented positive clinical safety and immunogenicity data from from its collaborative phase 1 clinical study evaluating a universal vaccine candidate against covid-19, SVF-002. The study was carried out by the OpenCorona consortium in collaboration with Karolinska University Hospital in Stockholm. The positive results are an important milestone and validate SVF Vaccines development platform.
The market
Despite preventive vaccines and antiviral treatments, over 250 million people live with a chronic hepatitis B infection. Each year, one million chronic carriers of the virus die from complications. Today, 15-25 million people worldwide live with an infection of the closely related hepatitis D virus, that only infects hepatitis B-carriers and exacerbates the progression of the disease. The annual global market for hepatitis D is estimated at approximately USD 1 billion and the market for hepatitis B is estimated at USD 5–6 billion. The medical need for therapies for hepatitis B and D is significant.
Recent progress
A clear validation of SVFs development platform was achieved in October 2024, as the company presented positive clinical safety and immunogenicity data from the Open Corona collaborative phase 1 clinical study with the universal vaccine candidate against covid-19, SVF-002.
Expected milestones
Phase 1 study of hepatitis D vaccine is expected to be initiated in 2026.
Project HAnano Surface
Primary indication Implant surface coatings
Development phase Marketed
Holding in company* KDev Investments 12%
Other investors K-Svets Ventures Chalmers Ventures Riepen LCC Andra AP-fonden
Origin Chalmers University of Technology
More information promimic.com
*Fully-diluted ownership based on current investment plans
Promimic AB
Innovative surface treatment speeds up healing time of implants
Promimic (Gothenburg, Sweden) develops and commercializes HAnano Surface, a surface treatment that is currently used clinically on approximately 2 million implants. HAnano Surface is a nanometer-thin coating of hydroxylapatite crystals that stimulates the growth of bone cells. This provides a stronger anchoring in bone tissue and better healing. The surface is unique in that it can be applied to all types of implant materials and geometries, including porous materials and 3D printed structures – including surfaces where traditional, thicker HA coating can clog pores.
In the United States, the technology is approved by the FDA, which means that new implants with HAnano Surface can be quickly brought to market via a 510(k) process. This has enabled strong growth – and that the number of approved implants for clinical use continuously increases.
Promimic has a sales office in Austin, Texas and several partnerships for development and commercialization in the US market for orthopedic implants. Currently, the market for spinal implants is the company's strongest segment. The collaboration with the company's customers includes the development and commercialization of products treated with HAnano Surface technology in various application areas.
In the Brazilian market, Promimic collaborates with Sistema de Implante Nacional (S.I.N), a leading supplier of dental implants, which commercializes dental implants coated with HAnano Surface.
Promimic has been listed on Nasdaq First North Growth Market since 2022
The market
Promimic focuses on two main segments, namely the markets for orthopedic and dental implants. Together, these segments represent a global market opportunity for Promimic worth up to USD 600-800 million in 2025. Within these segments, the company's target group is medium to large sized implant companies and the main market is the United States.
Recent progress
- In February 2025, the company reported sales growth of 24% compared to the same period last year. Positive results were also published showing a reduction in bacterial growth on the company's implant surface HAnano Surface. The results are published in the scientific journal Journal of Functional Biomaterials.
- In April 2025, Promimic entered into a strategic license agreement with Lincotek to strengthen its market presence and expand sales channels in the orthopedic implant market.
- In May 2025, Promimic reported a 1.4 percent increase in sales for the first quarter compared to the same period the previous year, with revenues totaling SEK 8.8 million. The company also deepened its collaboration with Curiteva by extending their exclusive license agreement for coating 3D-printed PEEK implants with HAnano Surface.
Expected milestones
In 2025, the company is expected to run development projects with both existing and new customers, and further product launches and license agreements will be announced.
Financial Development
The following financial reporting is divided into one financial reporting for The Parent Company and one for The Investment Entity. The Parent Company and The Investment Entity are the same legal entity, but the reporting is divided to meet legal reporting requirements.
The Parent Company is reporting in accordance with the guidelines under the Swedish Annual Accounting Act and Swedish Financial Accounting Standards Council, RFR 2. The Investment Entity is required to meet the reporting requirements of listed companies and thus in accordance with IFRS adopted by the EU and the Swedish Annual Accounts Act
Amounts in brackets refer to the corresponding period the previous year unless otherwise stated.
Financial development in summary for the Investment Entity
| SEKm | 2025 | 2024 | 2025 | 2024 | 2024 |
|---|---|---|---|---|---|
| Apr-Jun | Apr-Jun | Jan-Jun | Jan-Jun | Full-year | |
| Condensed income statement | |||||
| Change in fair value of shares in portfolio | |||||
| companies | -11.5 | -11.1 | -15.0 | -9.2 | 1.6 |
| Net profit/loss | -73.3 | -16.0 | -87.5 | -15.8 | -8.1 |
| Balance sheet information | |||||
| Cash and cash equivalents | 71.1 | 49.7 | 71.1 | 49.7 | 42.0 |
| Net asset value (Note 1) | 1,148.6 | 1,238.2 | 1,148.6 | 1,238.2 | 1,245.0 |
| Net debt (Note 1) | -71.1 | -49.7 | -71.1 | -49.7 | -42.0 |
| Share information | |||||
| Earnings per share, weighted average | |||||
| before dilution (SEK) | -0.3 | -0.1 | -0.3 | -0.1 | 0.0 |
| Earnings per share, weighted average after dilution (SEK) |
-0.3 | -0.1 | -0.3 | -0.1 | 0.0 |
| Net asset value per share (SEK) (Note 1) | 4.3 | 4.6 | 4.3 | 4.6 | 4.6 |
| Equity per share (SEK) (Note 1) | 4.3 | 4.6 | 4.3 | 4.6 | 4.6 |
| Share price, last trading day in the reporting | |||||
| period (SEK) | 1.0 | 1.4 | 1.0 | 1.4 | 1.0 |
| Portfolio information | |||||
| Investments in portfolio companies | 1.8 | 10.7 | 17.3 | 22.7 | 62.0 |
| Of which investments not affecting cash flow | 1.8 | 1.2 | 3.5 | 2.5 | 5.2 |
| Portfolio companies at fair value through | |||||
| profit or loss | 1,058.9 | 1,113.9 | 1,058.9 | 1,113.9 | 1,120.8 |
Financial Development for the Investment Entity in 2025
Investments (comparable numbers 2024)
Investments in the portfolio in the second quarter 2025 by external investors and Karolinska Development amounted to SEK 159.9 (38.7) million, whereof 99% (72%) by external investors.
Karolinska Development invested during the second quarter 2025 SEK 1.8 (10.7) million, of which SEK 0.0 (9.5) million was cash investments. Non-cash investments (accrued interest on loans) amounted to SEK 1.8 (1.2) million.
Investments by external investors in the portfolio companies during the second quarter 2025 amounted to SEK 158.1 (28.0) million and were made in OssDsign with SEK 158.1 million.
During the year, Karolinska Development and external investors have made investments in the portfolio companies as follows:
| SEKm | Karolinska Development |
External Investors | Total Invested Q1-Q2 2025 |
|---|---|---|---|
| Modus Therapeutics | 5.3 | 0.0 | 5.3 |
| Dilafor | 4.5 | 6.7 | 11.3 |
| Boost Pharma | 3.4 | 3.4 | 6.8 |
| SVF Vaccines | 2.2 | 0.0 | 2.2 |
| Umecrine Cognition | 1.9 | 0.0 | 1.9 |
| OssDsign | 0.0 | 158.1 | 158.1 |
| Total | 17.3 | 168.2 | 185.5 |
Portfolio Fair Value
Fair Value of the portfolio companies owned directly by Karolinska Development had a net decrease by SEK 34.5 million during the second quarter 2025. The main reason for the decrease in fair value was the divestment of OssDsign, as well as the downturn in share price in the listed holding Modus Therapeutics.
Fair Value of the portfolio companies owned indirectly via KDev Investments decreased by SEK 14.8 million during the second quarter 2025. The main reason for the decrease in Fair value of the portfolio companies was the downturn in share price in the listed holding Promimic.
Total Fair Value from portfolio companies owned directly by Karolinska Development and indirectly via KDev Investments decreased by SEK 49.3 million in the second quarter 2025.
As a consequence of the decrease in Fair Value of the part of the portfolio owned via KDev Investments, the potential distribution to Rosetta Capital decreased by SEK 5.2 million, resulting in Net Portfolio Fair Value decreasing by SEK 44.2 million in the second quarter 2025.
| SEKm | 30 Jun 2025 | 31 Mar 2025 | Q2 2025 vs Q1 2025 |
|---|---|---|---|
| Karolinska Development Portfolio Fair Value (unlisted companies) | 815.8 | 819.0 | -3.2 |
| Karolinska Development Portfolio Fair Value (listed companies) | 33.8 | 65.1 | -31.3 |
| KDev Investments Portfolio Fair Value | 535.2 | 550.1 | -14.8 |
| Total Portfolio Fair Value | 1,384.9 | 1,434.2 | -49.3 |
| Potential distribution to Rosetta Capital of fair value of KDev Investments |
-325.9 | -331.1 | 5.2 |
| Net Portfolio Fair Value (after potential distribution to Rosetta Capital) | 1,058.9 | 1,103.1 | -44.2 |
Profit development 2025 (comparable numbers 2024)
During the second quarter of 2025, Karolinska Development's revenue amounted to SEK 0.4 (0.5) million and consists primarily of services provided to portfolio companies. For the period January - June 2025 the revenue amounted to SEK 0.9 (1.0) million.
Change in fair value of shares in portfolio companies of in total SEK -11.5 (-11.1) million includes the difference between the change in Net Portfolio Fair Value during the second quarter of 2025 with SEK -44.2 million and the investment in portfolio companies of SEK 1.8 million and divested portfolio companies of SEK 34.5 million. For the period January - June 2025 the change in fair value of shares in portfolio companies amounted to SEK -15.0 (-9.2) million.
Interest income on loans to portfolio companies amounted to SEK 1.8 million during the second quarter of 2025 (0.0 for the second quarter of 2024 as these are reported in net financial items). For the period January - June 2025 the interest income on loans to portfolio companies amounted to SEK 3.5 million (SEK 0.0 as these are reported in financial items).
Change in fair value of other financial assets and liabilities amounted to SEK -57.6 (2.0) million and were the consequence of changes in valuation of earn-out deals. The result is mainly due to the valuation of the earn-
out agreement with Organon (regarding the sale of Forendo) after Organon announced that they plan to discontinue the OG-6219 clinical development program. Change in fair value of other financial assets and liabilities for the period January – June 2025 amounted to SEK -63.7 (6.9) million.
During the second quarter of 2025 other expenses amounted to SEK 1.7 (2.2) million and personnel costs amounted to SEK 4.5 (6.5) million. The reduced personnel costs during the quarter compared to the previous year are the effect of personnel being made redundant. For the period January – June 2025 other expenses amounted to SEK 3.2 (3.6) million and personnel cost amounted to 9.7 (13.7) million.
The operating profit/loss in the second quarter of 2025 amounted to SEK -73.4 million compared to SEK -17.5 million in the second quarter 2024. The operating profit/loss for the period January - June 2025 amounted to -87.7 (-19.0) million.
The financial net during the second quarter of 2025 amounted to SEK 0.1 million (interest income on loans to portfolio companies is reported on a separate line in operation profit/loss) compared to SEK 1.5 million in the second quarter of 2024 (of which interest income on loans to portfolio companies amounted to SEK 1.5 million). The financial net for the period January - June 2025 amounted to SEK 0.2 (3.2) million.
The Investment Entity's Net profit/loss amounted to SEK -73.3 (16.0) million in the second quarter of 2025. Net profit/loss for the period January - June 2025 amounted to SEK -87.5 (-15.8) million.
Financial position
The Investment Entity's equity to total assets ratio amounted to 99% on 30 June 2025, which it also did on 30 June 2024.
The investment company's equity on 30 June 2025 amounted to SEK 1,151.2 million, compared to SEK 1,224.5 million on 31 March 2025, a decrease by SEK -73.3 million. The decrease is a consequence of the profit/loss for the period of SEK -73.3 million.
After the paying of operational costs and investments for the second quarter 2025, cash and cash equivalents amounted to SEK 71.1 million on 30 June 2025 compared to SEK 49.7 million on 30 June 2024. Net debt (negative net debt/ net cash) amounted to SEK -71.1 million on 30 June 2025 compared to the net debt of SEK -49.7 million on 30 June 2024.
The company is going concern. We regularly review financing solutions, including in the form of the sale of shares and portfolio companies, the taking up of loans and/or the implementation of new share issues in order to continue to finance the portfolio companies in their development and enable new investments. The company's ability to continue operations (going concern) is stable, given current cash flow expectations and plans. The report is prepared based on the assumption of continued operation.
Financial Development – Parent Company
The Parent Company refers to Karolinska Development AB (comparable numbers 2024).
During the second quarter of 2025, the Parent Company's Net profit/loss amounted to SEK -73.3 (-16.0) million. The net profit/loss for the period January - June 2025 amounted to -87.5 (-15.8) million.
The negative result for the second quarter of 2025 led to a decrease in equity of SEK 73.3 million from SEK 1,224.5 million as of 31 March 2025 to SEK 1,151.2 million 30 June 2025. The decrease is a consequence of the profit/loss for the period of SEK -73.3 million.
The Share
The share and share capital
Trade in the Karolinska Development share takes place on Nasdaq Stockholm under the ticker symbol "KDEV". The last price paid for the listed B share on 30 June 2025 was SEK 1.0, and the market capitalization amounted to SEK 273 million.
The share capital of Karolinska Development on 30 June 2025 amounted to SEK 2.7 million divided into 2,555,261 A shares, each with ten votes (25,552,610 votes) and 267,522,333 B shares, each with one vote (267,522,333 votes). The total number of shares and votes in Karolinska Development on 30 June 2025 amounted to 270,077,594 shares and 293,074,943 votes.
Ownership
On 30 June 2025, Karolinska Development had 12,618 shareholders.
| Shareholder | A-Shares | B-Shares | Cap % | Vote % |
|---|---|---|---|---|
| invoX Pharma Ltd | 0 | 128,736,381 | 47.67% | 43.93% |
| Worldwide International Investments Ltd | 0 | 19,896,007 | 7.37% | 6.79% |
| Swedbank Robur Microcap fond | 0 | 8,750,000 | 3.24% | 2.99% |
| Styviken Invest | 0 | 5,236,206 | 1.94% | 1.79% |
| Avanza Pension | 0 | 5,175,556 | 1.92% | 1.77% |
| Stift För Främjande & Utveckling | 2,555,261 | 0 | 0.95% | 8.72% |
| Coastal Investment Management LLC | 0 | 2,470,541 | 0.91% | 0.84% |
| Steffensen Asset Management | 0 | 2,313,187 | 0.86% | 0.79% |
| Nordnet Pensionsförsäkring | 0 | 1,632,818 | 0.60% | 0.56% |
| Skandia Fonder | 0 | 1,175,313 | 0.44% | 0.40% |
| Sum Top 10 Shareholders | 2,555,261 | 175,386,009 | 65.89% | 68.56% |
| Sum Other Shareholders | 0 | 92,136,324 | 34.11% | 31.44% |
| Sum All Shareholders | 2,555,261 | 267,522,333 | 100.00% | 100.00% |
Information on Risks and Uncertainties
Investment Entity and Parent Company
Financial risks
Russia's invasion of Ukraine, as well as the war in Gaza and the related disturbances of sea transport through the Red Sea continue to affect the economy and society as a whole, including Karolinska Development and its portfolio companies. Also the US administration's policies and their effects, both domestically in the US, which is often the largest and most important market for new drugs, and the impact on world trade, primarily through the tariffs that might be introduced. The general downturn in the stock market since 2022 as well as the increase in interest rates since then have shifted the financial market's focus from growth companies to companies with positive operating cash flows, which has led to lower valuations in many previously highly valued growth companies, although the financial markets have not, as yet, been hit by the political and tariff turmoil. This affects Karolinska Development and its opportunities to not only finance its portfolio companies, but also to divest them at a suitable time for Karolinska Development.
The value of listed companies can decline delays in clinical trial programs may occur and the opportunities for refinancing can be hampered. The Board monitors the evolvement of the crises closely and Karolinska Development is working intensively to minimize the impact on the value of our investments and works continuously with different financing alternatives to secure the long-term capital requirement and thereby increase the degree of strategic and operational headroom for the future.
For a detailed description of other risks and uncertainties, see the Annual Report 2024.
| Signing of the report | |||
|---|---|---|---|
| Solna, 29 August 2025 | |||
| Benjamin Toogood Chairman |
Philip Duong | Anders Härfstrand | |
| Anna Lefevre Skjöldebrand | Will Zeng | Viktor Drvota CEO |
Dates for Publication of Financial Information
| Interim Report January – September 2025 | 14 November 2025 |
|---|---|
| Year-end Report 2025 | 13 February 2026 |
| Annual Report 2025 | 20 March 2026 |
| Interim Report January – March 2026 | 30 April 2026 |
| Interim Report January – June 2026 | 28 August 2026 |
| Interim Report January – September 2026 | 13 November 2026 |
Karolinska Development is required by law to publish the information in this interim report. The information was published on 29 August 2025.
This interim report, together with additional information, is available on Karolinska Development's website: www.karolinskadevelopment.com.
Note: This report is a translation of the Swedish interim report. In case of any discrepancies, the official Swedish version shall prevail.
Financial Statements
Condensed income statement for the Investment Entity
| SEK 000 | Note | 2025 Apr-Jun |
2024 Apr-Jun |
2025 Jan-Jun |
2024 Jan-Jun |
2024 Full-year |
|---|---|---|---|---|---|---|
| Revenue | 386 | 487 | 923 | 958 | 1,838 | |
| Change in fair value of shares in portfolio |
||||||
| companies | 2,3 | -11,481 | -11,078 | -14,953 | -9,213 | 1,579 |
| Interest income on loans to portfolio companies Change in fair value of other financial assets and |
5 | 1,832 | - | 3,460 | - | 5,202 |
| liabilities | 3 | -57,610 | 2,004 | -63,676 | 6,942 | 15,443 |
| Other expenses | -1,735 | -2,212 | -3,190 | -3,570 | -7,097 | |
| Personnel costs Depreciation of right-of |
-4,528 | -6,465 | -9,743 | -13,652 | -25,126 | |
| use assets | -250 | -250 | -499 | -499 | -997 | |
| Operating profit/loss | -73,386 | -17,514 | -87,678 | -19,034 | -9,158 | |
| Financial net | 5 | 70 | 1,522 | 168 | 3,250 | 1,057 |
| Profit/loss before tax | -73,316 | -15,992 | -87,510 | -15,784 | -8,101 | |
| Taxes | - | - | - | - | - | |
| NET PROFIT/LOSS FOR THE PERIOD |
-73,316 | -15,992 | -87,510 | -15,784 | -8,101 |
Condensed statement of comprehensive income for the Investment Entity
| SEK 000 | Note | 2025 Apr-Jun |
2024 Apr-Jun |
2025 Jan-Jun |
2024 Jan-Jun |
2024 Full-year |
|---|---|---|---|---|---|---|
| Net profit/loss for the period |
-73,316 | -15,992 | -87,510 | -15,784 | -8,101 | |
| Total comprehensive income/loss for the period |
-73,316 | -15,992 | -87,510 | -15,784 | -8,101 |
Earnings per share for the Investment Entity
| SEK | Note | 2025 Apr-Jun |
2024 Apr-Jun |
2025 Jan-Jun |
2024 Jan-Jun |
2024 Full-year |
|---|---|---|---|---|---|---|
| Earnings per share, weighted average before dilution Number of shares, |
-0.27 | -0.06 | -0.32 | -0.06 | -0.03 | |
| weighted average before dilution Earnings per share, weighted average after |
269,833,309 269,833,309 269,833,309 269,833,309 269,833,309 | |||||
| dilution Number of shares, weighted average after |
-0.27 | -0.06 | -0.32 | -0.06 | -0.03 | |
| dilution | 269,833,309 269,833,309 269,833,309 269,833,309 269,833,309 |
Condensed balance sheet for the Investment Entity
| SEK 000 | Note | 30 Jun 2025 | 30 Jun 2024 | 31 Dec 2024 |
|---|---|---|---|---|
| ASSETS | ||||
| Tangible assets | ||||
| Right-of-use assets | 1,662 | 2,659 | 2,161 | |
| Financial assets | ||||
| Shares in portfolio companies at fair value | ||||
| through profit or loss | 2,3 | 1,058,948 | 1,113,915 | 1,120,777 |
| Other financial assets | 4 | 9,039 | 64,711 | 71,271 |
| Total non-current assets | 1,069,649 | 1,181,285 | 1,194,209 | |
| Current assets | ||||
| Receivables from portfolio companies | 1,911 | 434 | 1,126 | |
| Other financial assets | 4 | 9,584 | 10,037 | 11,084 |
| Other current receivables | 6,836 | 1,053 | 2,400 | |
| Prepaid expenses and accrued income | 1,353 | 1,926 | 1,151 | |
| Cash and cash equivalents | 71,107 | 49,717 | 42,010 | |
| Total current assets | 90,791 | 63,167 | 57,771 | |
| TOTAL ASSETS | 1,160,440 | 1,244,452 | 1,251,980 | |
| EQUITY AND LIABILITIES | ||||
| Total equity | 1,151,213 | 1,231,040 | 1,238,723 | |
| Current liabilities | ||||
| Other financial liabilities | 44 | 190 | 100 | |
| Accounts payable | 472 | 1,282 | 762 | |
| Liability to make lease payment | 1,858 | 2,595 | 2,112 | |
| Other current liabilities | 1,618 | 1,754 | 684 | |
| Accrued expenses and prepaid income | 5,235 | 7,591 | 9,599 | |
| Total current liabilities | 9,227 | 13,412 | 13,257 | |
| Total liabilities | 9,227 | 13,412 | 13,257 | |
| TOTAL EQUITY AND LIABILITIES | 1,160,440 | 1,244,452 | 1,251,980 |
Condensed statement of changes in the Investment Entity's equity
| SEK 000 | Not | 30 Jun 2025 | 30 Jun 2024 | 31 Dec 2024 |
|---|---|---|---|---|
| Opening balance, equity | 1,238,723 | 1,246,824 | 1,246,824 | |
| Share capital | 2,701 | 2,701 | 2,701 | |
| Share premium | 2,735,903 | 2,735,903 | 2,735,903 | |
| Retained earnings | -1,587,391 | -1,507,564 | -1,499,881 | |
| Closing balance, equity | 1,151,213 | 1,231,040 | 1,238,723 |
INTERIM REPORT Jan – Jun 2025
Condensed statement of cash flows for the Investment Entity
| SEK 000 | Note | 2025 Jan-Jun |
2024 Jan-Jun |
2024 Full-year |
|---|---|---|---|---|
| Operating activities | ||||
| Operating profit/loss | -87,678 | -19,034 | -9,158 | |
| Adjustments for items not affecting cash flow | ||||
| Depreciation | 499 | 499 | 997 | |
| Change in fair value | 78,629 | 2,271 | -17,022 | |
| Other items | -3,425 | 270 | -4,040 | |
| Cash flow from operating activities before changes in | ||||
| working capital and operating investments | -11,975 | -15,994 | -29,223 | |
| Cash flow from changes in working capital | ||||
| Increase (-)/Decrease (+) in operating receivables | -5,252 | -1,113 | -1,284 | |
| Increase (+)/Decrease (-) in operating liabilities | -3,482 | 2,269 | 2,677 | |
| Cash flow from operating activities | -20,709 | -14,838 | -27,830 | |
| Investment activities | ||||
| Part payment from earn-out deal | - | 82 | 887 | |
| Proceeds from sale of shares in portfolio companies | 64,212 | - | 41,497 | |
| Acquisitions of shares in portfolio companies | -13,875 | -20,253 | -56,753 | |
| Cash flow from investment activities | 50,337 | -20,171 | -14,369 | |
| Financing activities | ||||
| Amortization of lease liabilities | -531 | -546 | -1,063 | |
| Cash flow from financing activities | -531 | -546 | -1,063 | |
| Cash flow for the period | 29,097 | -35,555 | -43,262 | |
| Cash and cash equivalents at the beginning of the year | 42,010 | 85,272 | 85,272 | |
| CASH AND CASH EQUIVALENTS AT THE END OF | ||||
| THE PERIOD | 71,107 | 49,717 | 42,010 |
INTERIM REPORT Jan – Jun 2025
Condensed income statement for the Parent Company
| SEK 000 | Note | 2025 Apr-Jun |
2024 Apr-Jun |
2025 Jan-Jun |
2024 Jan-Jun |
2024 Full-year |
|---|---|---|---|---|---|---|
| Revenue | 387 | 487 | 923 | 958 | 1,838 | |
| Change in fair value of shares in portfolio companies |
2,3 | -11,481 | -11,078 | -14,953 | -9,213 | 1,579 |
| Interest income on loans to portfolio companies Change in fair value of other financial assets and |
1,832 | - | 3,460 | - | 5,202 | |
| liabilities | -57,610 | 2,004 | -63,676 | 6,942 | 15,443 | |
| Other expenses | -2,002 | -2,478 | -3,721 | -4,102 | -8,160 | |
| Personnel costs | -4,528 | -6,465 | -9,743 | -13,652 | -25,126 | |
| Operating profit/loss | -73,402 | -17,530 | -87,710 | -19,067 | -9,224 | |
| Financial net | 88 | 1,550 | 206 | 3,308 | 1,162 | |
| Profit/loss before tax | -73,314 | -15,980 | -87,504 | -15,759 | -8,062 | |
| Tax | - | - | - | - | - | |
| NET PROFIT/LOSS FOR THE PERIOD |
-73,314 | -15,980 | -87,504 | -15,759 | -8,062 |
Condensed statement of comprehensive income for the Parent Company
| SEK 000 | Note | 2025 Apr-Jun |
2024 Apr-Jun |
2025 Jan-Jun |
2024 Jan-Jun |
2024 Full-year |
|---|---|---|---|---|---|---|
| Net profit/loss for the period | -73,314 | -15,980 | -87,504 | -15,759 | -8,062 | |
| Total comprehensive income/loss for the period |
-73,314 | -15,980 | -87,504 | -15,759 | -8,062 |
Condensed balance sheet for the Parent Company
| SEK 000 | Note | 30 Jun 2025 | 30 Jun 2024 | 31 Dec 2024 |
|---|---|---|---|---|
| ASSETS | ||||
| Financial non-current assets | ||||
| Shares in portfolio companies at fair value | ||||
| through profit or loss | 2,3 | 1,058,948 | 1,113,915 | 1,120,777 |
| Other financial assets | 4 | 9,039 | 64,711 | 71,271 |
| Total non-current assets | 1,067,987 | 1,178,626 | 1,192,048 | |
| Current assets | ||||
| Receivables from portfolio companies | 1,911 | 434 | 1,127 | |
| Other financial assets | 4 | 9,584 | 10,037 | 11,084 |
| Other current receivables | 6,836 | 1,053 | 2,400 | |
| Prepaid expenses and accrued income | 1,353 | 1,926 | 1,151 | |
| Cash and cash equivalents | 71,107 | 49,717 | 42,010 | |
| Total current assets | 90,791 | 63,167 | 57,772 | |
| TOTAL ASSETS | 1,158,778 | 1,241,793 | 1,249,820 | |
| EQUITY AND LIABILITIES | ||||
| Total equity | 1,151,169 | 1,230,977 | 1,238,673 | |
| Current liabilities | ||||
| Other financial liabilities | 44 | 190 | 100 | |
| Accounts payable | 472 | 1,282 | 762 | |
| Other current liabilities | 1,858 | 1,753 | 686 | |
| Accrued expenses and prepaid income | 5,235 | 7,591 | 9,599 | |
| Total current liabilities | 7,609 | 10,816 | 11,147 | |
| Total liabilities | 7,609 | 10,816 | 11,147 | |
| TOTAL EQUITY AND LIABILITIES | 1,158,778 | 1,241,793 | 1,249,820 |
Condensed statement of changes in equity for the Parent Company
| SEK 000 | Not | 30 Jun 2025 | 30 Jun 2024 | 31 Dec 2024 |
|---|---|---|---|---|
| Opening balance, equity | 1,238,673 | 1,246,736 | 1,246,735 | |
| Share capital | 2,701 | 2,701 | 2,701 | |
| Share premium reserve | 2,735,903 | 2,735,903 | 2,735,903 | |
| Retained earnings | -1,587,435 | -1,507,627 | -1,499,931 | |
| Closing balance, equity | 1,151,169 | 1,230,977 | 1,238,673 |
Notes to the Financial Statements
NOTE 1 Accounting policies
This report has been prepared in accordance with the International Accounting Standard (IAS) 34 Interim Financial Reporting and the Annual Accounts Act. The accounting policies applied to the Investment Entity and the Parent Company correspond, unless otherwise stated below, to the accounting policies and valuation methods used in the preparation of the most recent annual report.
Information on the Parent Company
Karolinska Development AB (publ) ("Karolinska Development," "Investment Entity" or the "Company") is a Nordic life sciences investment company. The Company, with Corporate Identity Number 556707-5048, is a limited liability company with its registered office in Solna, Sweden. The Company focuses on identifying medical innovations and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients' lives and provide an attractive return on investment to its shareholders. The sole purpose of investing in such companies is to generate a return through capital appreciation and investment income. These temporary investments, which are not investment entities, are designated "portfolio companies" below.
New and revised accounting principles 2025
No new or revised IFRS standards or recommendations from IFRS Interpretations Committee have had significant impact on the Investment Entity.
Related party transactions
No related party transactions other than compensation for management and the board have taken place during the reporting period.
Definitions
Interim period: The period from the beginning of the financial year through the closing date.
Reporting period: January - June 2025.
Alternative Performance Measures
The Company presents certain financial measures in the interim report that are not defined under IFRS. The Company believes that these measures provide useful supplemental information to investors and the company's management as they allow for the evaluation of the company's performance. Because not all companies calculate the financial measures in the same way, these are not always comparable to measures used by other companies. Therefore, these financial measures should not be considered as substitutes for measures as defined under IFRS.
Portfolio companies: Companies where Karolinska Development has made investments (subsidiaries, joint ventures, associated companies and other long-term securities' holdings) which are active in pharmaceuticals, MedTech, theranostics and formulation technology.
The Portfolio Fair Value is divided into Total Portfolio Fair Value and Net Portfolio Fair Value.
Total Portfolio Fair Value: The aggregated proceeds that would be received by Karolinska Development and KDev Investments if the shares in their portfolio companies were sold in an orderly transaction between market participants at the measurement date.
Net Portfolio Fair Value (after potential distribution to Rosetta Capital) is the net aggregated proceeds that Karolinska Development will receive after KDev Investments' distribution of proceeds to Rosetta Capital.
rNPV: "risk-adjusted net present value" is a method to value risky future cash flows. rNPV is the standard valuation method in the drug development industry, where sufficient data exists to estimate success rates for all R&D phases.
Equity per share: Equity on the closing date in relation to the number of shares outstanding on the closing date.
Net debt: Interest-bearing liabilities (SEK 0.0 million) reduced with cash and cash (SEK 71.1 million).
Equity to total assets ratio: Equity divided by total assets.
Net asset value as of 30 June 2025:
| Number of shares |
Fair value | Part of Karolinska Developments' net asset value |
|||
|---|---|---|---|---|---|
| SEK 000 | SEK per share3 |
percentage | |||
| Listed assets | |||||
| Modus Therapeutics | 23,801,390 | 33,849 | 0.13 | 2.9% | |
| Total listed assets | 33,849 | 0.13 | 2.9% | ||
| Unlisted assets AnaCardio Boost Pharma Dilafor PharmNovo SVF Vaccines Umecrine Cognition KCIF Co-Investment Fund KB1 KDev Investments1 |
60,628 10,125 50,420 35,177 28,268 627,547 3,622 209,312 |
0.22 0.04 0.19 0.13 0.10 2.33 0.01 0.78 |
5.3% 0.9% 4.4% 3.1% 2.5% 54.6% 0.3% 18.2% |
||
| Total unlisted assets | 1,025,099 | 3.80 | 89.2% | ||
| Net of other liabilities and debts2 | 89,686 | 0.33 | 7.8% | ||
| Total net asset value | 1,148,634 | 4.26 | 100.0% |
1The company has both listed and unlisted assets.
2 Includes SEK 71.1 million cash and cash equivalents.
3In relation to the number of shares outstanding (269,833,309) on the closing date.
NOTE 2 Shares in portfolio companies, at fair value through profit or loss
Change in fair value of portfolio companies
| 2025 | 2024 | 2025 | 2024 | 2024 | |
|---|---|---|---|---|---|
| SEK 000 | Apr-Jun | Apr-Jun | Jan-Jun | Full-year | Jan-Jun |
| Result level 1 | |||||
| Listed companies, realized | 6,008 | - | 8,962 | - | 8,383 |
| Listed companies, unrealized | -2,976 | -8,532 | -10,902 | -4,103 | 843 |
| Total level 1 | 3,032 | -8,532 | -1,940 | -4,103 | 9,226 |
| Result level 3 | |||||
| Unlisted companies, realized | -5,150 | 80 | -5,580 | 803 | -1,245 |
| Unlisted companies, unrealized | -9,363 | -2,626 | -7,433 | -5,913 | -6,402 |
| Total level 3 | -14,513 | -2,546 | -13,013 | -5,110 | -7,647 |
| Total | -11,481 | -11,078 | -14,953 | -9,213 | 1,579 |
Shares in portfolio companies, at fair value through profit or loss
| SEK 000 | 30 Jun 2025 | 30 Jun 2024 | 31 Dec 2024 |
|---|---|---|---|
| Accumulated acquisition cost | |||
| At the beginning of the year | 1,120,777 | 1,100,398 | 1,100,398 |
| Investments during the year | 17,335 | 22,730 | 61,998 |
| Sales during the year | -64,212 | - | -43,197 |
| Changes in fair value in net profit/loss for the | |||
| year | -14,953 | -9,213 | 1,579 |
| Closing balance | 1,058,948 | 1,113,915 | 1,120,777 |
NOTE 3 Fair value
The table below shows financial instruments measured at fair value based on the classification in the fair value hierarchy. The various levels are defined as follows:
- Level 1- Fair value determined on the basis of observed (unadjusted) quoted prices in an active market for identical assets and liabilities
- Level 2- Fair value determined based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly
- Level 3- Fair value determined based on valuation models where significant inputs are based on non‐ observable data
Fair value as of 30 June 2025
| SEK 000 | Level 1 | Level 2 | Level 3 | Total |
|---|---|---|---|---|
| Financial assets | ||||
| Shares in portfolio companies, at fair value | ||||
| through profit or loss | 33,849 | - | 1,025,099 | 1,058,948 |
| Other financial assets | - | - | 18,623 | 18,623 |
| Cash and cash equivalents | 71,107 | - | - | 71,107 |
| Total | 104,956 | 0 | 1,043,722 | 1,148,678 |
| Financial liabilities | ||||
| Other financial liabilities | - | - | 44 | 44 |
| Total | - | 0 | 44 | 44 |
Fair value as of 30 June 2024
| SEK 000 | Level 1 | Level 2 | Level 3 | Total |
|---|---|---|---|---|
| Financial assets | ||||
| Shares in portfolio companies, at fair value through profit or loss |
120,495 | - | 993,420 | 1,113,915 |
| Other financial assets | - | - | 74,748 | 74,748 |
| Cash, cash equivalents | 49,717 | - | - | 49,717 |
| Total | 170,212 | 0 | 1,068,168 | 1,238,380 |
| Financial liabilities Other financial liabilities |
- | - | 190 | 190 |
| Total | - | 0 | 190 | 190 |
Fair value as of 31 December 2024
| SEK 000 | Level 1 | Level 2 | Level 3 | Total |
|---|---|---|---|---|
| Financial assets | ||||
| Shares in portfolio companies, at fair value through profit or loss |
94,713 | - | 1,026,064 | 1,120,777 |
| Other financial assets | - | - | 82,355 | 82,355 |
| Cash and cash equivalents | 42,010 | - | - | 42,010 |
| Total | 136,723 | 0 | 1,108,419 | 1,245,142 |
| Financial liabilities | ||||
| Other financial liabilities | - | - | 100 | 100 |
| Total | - | 0 | 100 | 100 |
Fair value (level 3) as of 30 June 2025
| Shares in portfolio companies |
Other financial assets |
Other financial liabilities |
|---|---|---|
| 1,026,064 | 82,355 | 100 |
| 12,049 | - | - |
| -13,013 | -63,732 | -56 |
| 1,025,099 | 18,623 | 44 |
| -5,580 | 0 | 0 |
| 56 | ||
| -7,433 | -63,732 |
Fair value (level 3) as of 30 June 2024
| SEK 000 | Shares in portfolio companies |
Other financial assets |
Other financial liabilities |
|---|---|---|---|
| At beginning of the year | 975,800 | 67,829 | 130 |
| Acquisitions | 22,730 | - | - |
| Compensations | - | -82 | - |
| Gains and losses recognized through profit or loss | -5,110 | 7,001 | 60 |
| Closing balance 30 June 2024 | 993,420 | 74,748 | 190 |
| Realized gains and losses for the period included in profit or loss |
803 | 82 | - |
| Unrealized gains and losses in profit or loss for the period included in profit or loss |
-5,913 | 6,919 | -60 |
Fair value (level 3) as of 31 December 2024
| SEK 000 | Shares in portfolio companies |
Other financial assets |
Other financial liabilities |
|---|---|---|---|
| At the beginning of the year | 975,800 | 67,829 | 130 |
| Acquisitions | 61,998 | - | - |
| Compensations | -4,086 | -887 | - |
| Gains and losses recognized through profit or loss | -7,647 | 15,412 | -30 |
| Closing balance 31 December 2024 | 1,026,064 | 82,355 | 100 |
| Realized gains and losses for the period included in profit | |||
| or loss | -1,245 | 887 | - |
| Unrealized gains and losses in profit or loss for the period included in profit or loss |
-6,402 | 14,525 | 30 |
The Investment Entity recognizes transfers between levels in the fair value hierarchy on the date when an event or changes occur that give rise to the transfer.
Shares in portfolio companies (Level 3) as of 30 June 2025
| SEK 000 | Ownership | Market value | Valuation model1 |
|---|---|---|---|
| AnaCardio | 10.0% | 60,628 | Last post money |
| Boost Pharma | 13.6% | 10,125 | Last post money |
| Dilafor | 2.7% | 50,420 | Last post money |
| PharmNovo | 20.0% | 35,177 | Last post money |
| SVF Vaccines | 32.7% | 28,268 | Last post money |
| Umecrine Cognition | 72.6% | 627,547 | External valuation2 |
| KCIF Co-Investment Fund KB | 26.0% | 3,622 | A combination of share price |
| listed company and fair value of | |||
| KDev Investments | 90.1% | 209,312 | financial asset3 A combination of last post |
| money and share price listed | |||
| company4 | |||
| Total level 3 | 1,025,099 |
1See The Annual Report 2024 Valuation of portfolio companies at fair value, for a description of valuation models. 2Risk-adjusted external valuation model from an independent valuation institute December 2024. The rNPV value from the model adjusted further in order to reflect an assumed split in risk and revenues in conjunction with e.g. a license deal and also to incorporate the financial risk that Umecrine Cognition will not manage to finance fully the final parts of the research program. 3KCIF Co-Investment Fund KB holds listed shares which are valued in accordance with the closing rate on the final trading day of the period and a financial asset, at fair value through profit or loss, attributable to earn-out in the sale of Forendo Pharma. 4KDev Investments AB holds both listed shares which are valued in accordance with the closing rate on the final trading day of the period and unlisted shares which are valued in accordance with the most recent transaction (post-money valuation). Dilafor, which is an unlisted company, accounts for 91% of the total fair value of KDev Investments.
Sensitivity analysis of significant holdings 30 June 2025
| +/-5% Result/ equity |
+/-15% Result/ equity |
+/- 30% | ||||
|---|---|---|---|---|---|---|
| Result/ equity | ||||||
| KSEK | SEK/ share | KSEK | SEK/ share | KSEK | SEK/ share | |
| Umecrine Cognition1 | +/-33,572 | +/-0.1 | +/-100,715 | +/-0.4 | +/-201,431 | +/-0.7 |
| KDev Investments2 | +/-17,905 | +/-0.1 | +/-53,615 | +/-0.2 | +/-107,330 | +/-0.4 |
1) Sensitivity to rNPV value in performed valuation based on the assumed sales price of the drug. 2) Sensitivity in the value of KDev Investments, after potential distribution to Rosetta Capital.
Sensitivity analysis of significant holdings 31 December 2024
| +/-5% | +/-15% | +/- 30% | ||||
|---|---|---|---|---|---|---|
| Result/ equity | Result/ equity | Result/ equity | ||||
| KSEK | SEK/ share | KSEK | SEK/ share | KSEK | SEK/ share | |
| Umecrine | +/- | |||||
| Cognition1 | +/-33,572 | +/-0.1 | 100,715 | +/-0.4 | +/-201,431 | +/-0.7 |
| KDev Investments2 | +/-17,950 | +/-0.1 | +/-53,550 | +/-0.2 | +/-107,100 | +/-0.4 |
1) Sensitivity to rNPV value in performed valuation based on the assumed sales price of the drug. 2) Sensitivity in the value of KDev Investments, after potential distribution to Rosetta Capital.
Impact of Portfolio Fair Value
In the table below, "Total Portfolio Fair Value" is as defined in Note 1.
Impact on Portfolio Fair Value of the agreement with Rosetta Capital
"Potential distribution to Rosetta Capital", SEK 325.9 million, is the amount that KDev Investments according to the investment agreement between Karolinska Development and Rosetta Capital is obliged to distribute to Rosetta Capital from the proceeds received by KDev Investments (KDev Investments Fair Value). The distribution to Rosetta Capital will only happen when KDev Investments distributes dividends. KDev Investments will only distribute dividends after all eventual payables and outstanding debt has been repaid. Following dividends from KDev Investments during 2021 - 2023, all additional investments totaling SEK 43.7 million have been repaid to Rosetta Capital. In addition, SEK 6.7 million has been distributed, which reduces the first SEK 220 million in the waterfall structure. See also the annual report for 2024, note 16, for a description of the agreement with Rosetta Capital.
"Net Portfolio Fair Value (after potential distribution to Rosetta Capital)" is as defined in Note 1.
Expanded Portfolio Fair Value calculations taking the portfolio valuation and potential distribution to Rosetta Capital in consideration
| SEK 000 | 30 Jun 2025 | 30 Jun 2024 | 31 Dec 2024 |
|---|---|---|---|
| Karolinska Development Portfolio Fair Value (unlisted companies) | 815,786 | 758,579 | 807,798 |
| Karolinska Development Portfolio Fair Value (listed companies) | 33,849 | 120,495 | 94,713 |
| KDev Investments Portfolio Fair Value | 535,243 | 574,962 | 549,021 |
| Total Portfolio Fair Value | 1,384,878 | 1,454,036 | 1,451,532 |
| Potential distribution to Rosetta Capital of fair value of KDev | |||
| Investments | -325,930 | -340,121 | -330,754 |
| Net Portfolio Fair Value (after potential distribution to Rosetta Capital) | 1,058,948 | 1,113,915 | 1,120,777 |
NOTE 4 Other financial assets
| SEK 000 | 30 Jun 2025 | 30 Jun 2024 | 31 Dec 2024 |
|---|---|---|---|
| Other financial assets, non-current | |||
| Earn-out agreement Forendo Pharma | 9,039 | 64,711 | 71,271 |
| Earn-out agreement Oncopeptides | - | 0 | 0 |
| Total | 9,039 | 64,711 | 71,271 |
| Other financial assets, current | |||
| Earn-out agreement Forendo Pharma | 9,584 | 10,037 | 11,084 |
| Total | 9,584 | 10,037 | 11,084 |
| Total other financial assets | 18,623 | 74,748 | 82,355 |
Earn-out agreement Forendo Pharma
Karolinska Development is entitled to earn-out payments according to the agreement with Organon regarding the sale of Forendo Pharma. Karolinska Development estimates the risk-adjusted net present value (rNPV) of future cash flows (earn-outs), after the initial payment in December 2021 and payments in 2022 and 2023, to SEK 18.6 million, whereof Karolinska Development expects SEK 9.6 million to be paid during the next 12 months. The earn-outs are expected to be paid during the period 2025–2034, and renewed rNPV valuations will be performed continuously. Forendo Pharma's previous shareholders were entitled to additional future payments upon the achievement of certain development, registration and commercial milestones pertaining to Forendo Pharma's drug candidates. Following Organon's update regarding the development of the drug candidate OG-6219, which is based on results from a Phase 2 clinical study in endometriosis-related pain, Organon plans to discontinue the development program with OG-6219, resulting in a fair value adjustment for Karolinska Development by SEK -57.6 million as the acquisition agreement included the right to an additional purchase price. The acquisition of Forendo included two drug candidates, of which OG-6219 was the most advanced drug project.
Earn-out agreement Oncopeptides
Karolinska Development was entitled to earn-out payments according to the agreement with Industrifonden regarding the previous holdings in Oncopeptides. The agreement was finalized in the third quarter of 2024.
NOTE 5 Interest income on loans to portfolio companies1)
| SEK 000 | 2025 Apr-Jun |
2024 Apr-Jun |
2025 Jan-Jun |
2024 Jan-Jun |
2024 Full-year |
|---|---|---|---|---|---|
| Net operations | |||||
| Interest on loans to portfolio companies | 1,832 | - | 3,460 | - | 5,202 |
| Total | 1,832 | 0 | 3,460 | 0 | 5,202 |
| Financial net Interest on loans to portfolio companies and other interest |
70 | 1,522 | 168 | 3,250 | 1,057 |
| Total | 70 | 1,522 | 168 | 3,250 | 1,057 |
1) Interest income on loans to portfolio companies is reported as of the fourth quarter of 2024 as a separate item in operating profit/loss (interest on loans to portfolio companies during the second quarter of 2024 amounted to KSEK 1,218 and for the period January – June 2024 KSEK 2,477). Other interest income is reported in net financial items.
NOTE 6 Pledge assets and contingent liabilities
| SEK 000 | 30 Jun 2025 | 30 Jun 2024 | 31 Dec 2024 |
|---|---|---|---|
| Pledge assets | |||
| Contingent liabilities | |||
| Loan to portfolio company | 26,454 | - | - |
| Loan commitment to portfolio company | - | - | 5,000 |
| Investment agreement in portfolio company | - | 18,500 | - |
| Summa | 26,454 | 18,500 | 5,000 |